Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Montgomery Advertiser on MSN20h
Alabama still fighting HIV: 'In the South is where we have the majority of the problems':Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
HIV is currently the only disease carrying a felony charge if someone knowingly transmits it to another person. The Senate ...
HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
1don MSN
A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...
A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, saying they are "doing catastrophic harm" to the global fight against AIDS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback